Skip to content
Immunomodulatory Peptides advanced

Sirolimus

Macrolide immunosuppressant that inhibits mTOR to block T-cell proliferation in transplant rejection and coronary stent coatings.

By Encyclopeptide Editorial | 2 min read
immunosuppressant mTOR-inhibitor transplant macrolide rapamycin

Chemical Identity

PropertyValue
Chemical FormulaC51H79NO13
Molecular Weight914.17 Da
CAS Number53123-88-9
Peptide ClassMacrolide (Polyketide-Peptide Hybrid)
OriginStreptomyces hygroscopicus

Structure

Sirolimus (rapamycin) is a 31-membered macrolide produced by Streptomyces hygroscopicus, first isolated from soil samples on Easter Island (Rapa Nui). It contains a pipecolic acid moiety and an unusual triene system. The molecule is structurally related to tacrolimus, sharing the FKBP12-binding domain but with an extended macrocyclic ring.

Mechanism of Action

Sirolimus binds to FKBP12, and the sirolimus-FKBP12 complex directly inhibits mTOR (mechanistic target of rapamycin) complex 1 (mTORC1). This blocks IL-2-mediated signal transduction, preventing T-cell progression from G1 to S phase. Unlike calcineurin inhibitors, sirolimus acts distal to cytokine receptor signaling.

Clinical Applications

  • Kidney transplant: Prevention of rejection (often with cyclosporine)
  • Coronary stents: Drug-eluting stent coating to prevent restenosis
  • Lymphangioleiomyomatosis: First-line therapy
  • Tuberous sclerosis: Renal angiomyolipomas and SEGAs

Pharmacokinetics

  • Half-life: 62 hours
  • Tmax: 1-2 hours (oral solution)
  • Bioavailability: 14% (tablet), 21% (solution)
  • Metabolism: CYP3A4 and P-glycoprotein substrate
  • Protein binding: 92%
  • Route: Oral, IV (stent coating)

Safety and Side Effects

Thrombocytopenia, hyperlipidemia (hypertriglyceridemia), delayed wound healing, oral ulcers, acne, pneumonitis, and increased infection risk. Does not cause nephrotoxicity like calcineurin inhibitors.

References

  • Sehgal, S.N. (2003). Sirolimus: from Easter Island to clinical practice. Expert Opinion on Pharmacotherapy, 4, 1327-1343.
  • Kahan, B.D. (2000). Sirolimus: a new agent for clinical transplantation. Transplantation Proceedings, 32, 2230-2233.

Test Your Knowledge

Reinforce what you learned about Sirolimus with interactive quizzes on Wikipept.

Take a Quiz on Wikipept